Brought to you by 
Kymab nabs £20mm from Wellcome Trust for Series A round
21 May 2021
Executive Summary
Wellcome Trust has provided monoclonal antibody developer Kymab Ltd. with £20mm ($30mm) in Series A financing. The start-up spun off from the Wellcome Trust Sanger Institute last year.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kymab nabs £20mm from Wellcome Trust for Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice